What is BioLyte Laboratories?
BioLyte Laboratories operates as a specialized pharmaceutical manufacturer, focusing on the development and production of over-the-counter (OTC) products derived from natural botanicals and minerals. The company distinguishes itself through a comprehensive service model that encompasses end-to-end formulation, production, and packaging. By maintaining rigorous adherence to Good Manufacturing Practices (GMP) and ISO standards, BioLyte Laboratories ensures that its output meets the highest quality benchmarks required by modern health-conscious consumers. Their technical team, comprised of expert product formulators and production specialists, enables the company to serve as a critical partner for brands seeking reliable, high-quality OTC manufacturing solutions in an increasingly regulated global market.
How much funding has BioLyte Laboratories raised?
BioLyte Laboratories has raised a total of $72K across 1 funding round:
Debt
$72K
Debt (2021): $72K with participation from PPP
Key Investors in BioLyte Laboratories
PPP
Public-Private Partnership
What's next for BioLyte Laboratories?
With the infusion of this recent capital, BioLyte Laboratories is expected to prioritize the scaling of its production infrastructure to meet rising demand for natural health products. The strategic focus will likely shift toward enhancing operational efficiencies and expanding its manufacturing capacity to support a broader client base. As the company navigates this Series B/C stage, the management team is anticipated to leverage these resources to optimize supply chain resilience and potentially invest in advanced R&D capabilities to further differentiate their botanical-based product portfolio. This growth phase is critical for establishing long-term market leadership and achieving sustainable profitability in the high-growth OTC manufacturing landscape.
See full BioLyte Laboratories company page
